CoChat
Sign Up
Cited by 569Dementia and Cognitive Impairment ResearchCancer-related cognitive impairment studiesHearing Loss and Rehabilitation

Mild cognitive impairment: Disparity of incidence and prevalence estimates

Ward, Alex, Arrighi, H. Michael, Michels, Shannon, Cedarbaum, Jesse M.·2012·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2011.01.002
Open this paper in CoChat — free account

Abstract

Background: The purpose of conducting this study was to identify areas of concordance and sources of variation for the published rates of prevalence and incidence associated with various definitions for mild cognitive impairment (MCI). Methods: The study used systematic review of studies published in English since 1984. Studies were identified by searching MEDLINE and EMBASE databases. Population‐based observational studies of incidence or prevalence of MCI and related terms were eligible for inclusion. Results: A total of 3,705 citations were identified, and 42 were accepted for inclusion; 35 included data on prevalence and 13 on incidence. The following four terms predominated: age‐associated memory impairment (AAMI); cognitive impairment no dementia (CIND); MCI; and amnestic MCI (aMCI). Within each term, the operational definition varied. Substantial variation was observed for both incidence (MCI: 21.5–71.3; aMCI: 8.5–25.9 per 1,000 person‐years) and prevalence of each definition of cognitive impairment (AAMI 3.6%–38.4%; CIND 5.1%–35.9%; MCI 3%–42%; aMCI 0.5%–31.9%). CIND and MCI showed increasing prevalence among older age groups, whereas age‐specific rates of aMCI were lower and without any apparent age relationship. Conclusions: Prevalence and incidence estimates associated with MCI vary greatly both between definitions and within a definition across the 42 publications. These wide differences pose a significant challenge to our understanding of the social burden of this disease. Enhancement and standardization of operational definitions of the subtypes of cognitive impairment could improve estimates of disease burden and provide a mechanism to assist in the identification of individuals at risk for future Alzheimer's disease and other dementias.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2011.01.002

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The percentage of older adults classified as MCI ranges greatly from 11% to 74% depending on the number of tests considered in the diagnosis and the cutoffs used to define objective cognitive impairment.

    “Jak and Bondi and colleagues [24, 25] have found that the percentage of older adults classified as MCI ranges greatly from 11% to 74% depending on the number of tests considered in the diagnosis and the cutoffs used to define objective cognitive impairment (see also [26]).”

    From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [26]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ward, A., Arrighi, H. M., Michels, S., & Cedarbaum, J. M.
Affiliations
  • United BioSource Corporation, Center for Epidemiology and Database Analytics Lexington MA USA
  • Elan Pharmaceuticals Inc South San Francisco CA USA
Corresponding author
Ward, Alex
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2012-01
Volume
8
Issue
1
Pages
14-21
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2011.01.002
OpenAlex
W2071639119
Cited by
569
References
5
Citations by year
2026: 22 · 2025: 25 · 2024: 31 · 2023: 39 · 2022: 51 · 2021: 56 · 2020: 70 · 2019: 40 · 2018: 22 · 2017: 34 · 2016: 46 · 2015: 43 · 2014: 42 · 2013: 37 · 2012: 10
FWCI
5.70
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Elan Pharmaceuticals, Inc
  • JANSSEN Alzheimer Immunotherapy acquired the Alzheimer Immunotherapy Program
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Hearing Loss and Rehabilitation
Keywords
mild cognitive impairment, prevalence
MeSH terms
Humans, Incidence, Prevalence, Databases, Bibliographic, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review